Good research practices for measuring drug costs in cost-effectiveness analyses: A societal perspective: The ISPOR drug cost task force report - Part II

Value in Health

Volumn 13, Issue 1, 2010, Pages 8-13

  Garrison Jr , Louis P ^a   Mansley, Edward C ^b   Abbott III, Thomas A ^c   Bresnahan, Brian W ^a   Hay, Joel W ^d   Smeeding, James ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c I3 Pharma Informatics   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e JestaRx Group   (United States)

Author keywords

Drug costs; Dynamic efficiency; Social costs; Societal perspective

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; MEDICAL PRACTICE; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW; SOCIAL WELFARE;

EID: 72949096583     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00660.x     Document Type: Article

References (18)

1. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine. New York : Oxford University Press, 1996.
2. Meltzer D, Johannesson M. Inconsistencies in the "societal perspective" on costs of the Panel on Cost-Effectiveness in Health and Medicine. Med Decis Making 1999 19 : 371 377.
3. Berger ML, Bingefors K, Hedblom EC, et al., eds. Health Care Cost, Quality, and Outcomes: ISPOR Book of Terms. Lawrenceville, NJ : International Society for Pharmacoeconomics and Outcomes Research, 2003.
4. Drummond MF, O'Brien B, Stoddard GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes (3rd ed.). Oxford : Oxford University Press, 2005.
5. Luce BR, Manning WG, Siegel JE, Lipscomb J. Estimating costs in cost-effectiveness analysis. In : Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine (Chapter 6). New York : Oxford University Press, 1996.
6. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997 16 : 1 33.
7. McGuire A. Theoretical concepts in the economic valuation of health care. In : Drummond M, McGuire A, eds. Economic Evaluation of Health Care: Merging Theory and Practice (Chapter 1). Oxford : Oxford University Press, 2001.
8. Brouwer WB, Culyer AJ, van Exel NJ, Rutten FF. Welfarism vs. extra-welfarism. J Health Econ 2008 27 : 325 338.
9. Landsburg SE. Price Theory and Applications. Orlando, FL : Dryden Press, 1989.
10. McCloskey DM. The Applied Theory of Price. New York : Macmillan Publishing Co., 1985.
11. Harberger A. Three basic postulates for applied welfare economics: an interpretive essay. J Econ Lit 1971 9 : 785 797.
12. Mansley EC, Abbott TA, III. Estimating drug cost in economic evaluations: price, acquisition cost, or marginal societal cost? Working paper, 2005.
13. Philipson TJ, Jena AB. Surplus appropriation from R&D and health care technology assessment procedures. NBER Working Paper #12016. January 2006.
14. Enthoven AC. Consumer-choice health plan. N Engl J Med 1978 298 : 650 658, 709 720.
15. Emanuel EJ, Fuchs VR. Health care vouchers - a proposal for universal coverage. N Engl J Med 2005 352 : 1255 1260.
16. Kremer M. Patent buyouts: a mechanism for encouraging innovation. Q J Econ 1998 1137 1167. (Pubitemid 128360921)
17. Hay J. Application of cost effectiveness and cost benefit analysis to pharmaceuticals. In : Santoro M, Gorrie T, eds. The Grand Bargain: Ethics and the Pharmaceutical Industry in the 21st Century (Chapter 8). New York : Cambridge University Press, 2006.
18. Danzon PM, Towse A. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int J Health Care Finance Econ 2003 3 : 183 205.